Ongoing Facial Angiofibroma Trials
See below for ongoing trials.
Clinical Trial for individuals diagnosed with Tuberous Sclerosis Complex (TSC) and cutaneous angiofibromas
We are currently conducting a clinical trial for individuals diagnosed with TSC with facial bumps called cutaneous angiofibromas. The goal of this study is to investigate if the study drug, sirolimus, improves cutaneous angiofibromas in individuals diagnosed with TSC. The trial is sponsored by a pharmaceutical company named Aucta Pharmaceuticals, Inc, and it will involve 6 to 8 centers including Boston Children’s Hospital, Children’s Hospital of Philadelphia, Le Bonheur Children’s Hospital, Children’s Hospital Colorado, Children’s Hospital Los Angeles, and Translational Genomic Research Institute.
We are looking to recruit individuals between the ages of 2 and 18 years who have TSC with cutaneous angiofibromas. If you/your child qualifies for the treatment phase of the trial after the initial screening visit, you/your child will be asked to take either the study ointment or a placebo (ointment with no medicine), which is determined by chance.
The study involves 4 visits to the hospital over a 4-month (16-week) timeframe. After completing the first phase of the study, you/your child will be offered the opportunity to participate in an optional 12-week open-label phase with sirolimus ointment. If you/your child agrees to participate in the open-label phase, you/your child will make 2 additional clinic visits bringing the total clinic visits to 6.
The study visits will involve blood draws, skin exams, vital signs, laboratory tests and other evaluations such as questionnaires and assessments. The study drug will be provided at no charge, and some compensation for travel expenses may be provided.
The following study sites are currently recruiting study participants. If you are interested in participating in this trial, please contact the following study coordinator and they will assist you with any questions you may have:
- Boston Children’s Hospital, Julia Costantini (617) 355-1494 email@example.com
- Children’s Hospital Philadelphia, Donnette Paris (267) 426-7167 firstname.lastname@example.org
- LeBonheur Children’s Hospital, Tracee Ridley-Pryor (901) 287-5338 Tracee.email@example.com
- Children’s Hospital Colorado, Shar Goodman (720) 777-5379 Sharolene.firstname.lastname@example.org
- Children’s Hospital Los Angeles, Martha Arellano-Garcia (323) 361-5812 email@example.com
- Translational Genomic Research Institute, Keri Ramsey (602) 343-8620 firstname.lastname@example.org
Dose-Ranging Efficacy and Safety Study of Topical Rapamycin Cream for Facial Angiofibroma Associated with Tuberous Sclerosis Complex (TSC)
A new clinical trial for individuals with TSC and facial angiofibromas who are 6 – 65 years old. Individuals who have used oral rapamycin/sirolimus, everolimus, or temsirolimus within 3 months of enrollment or have had laser surgery within 6 months of enrollment are not eligible to participate.
These locations in the United States are recruiting participants:
University of California San Diego
La Jolla, California, United States, 92037
Contact: Jessica Reit email@example.com
Principal Investigator: Doris Trauner
Grand Rapids, Michigan, United States, 49503
Contact: Christopher L Russell firstname.lastname@example.org
Principal Investigator: Steven DeRoos
Rochester, Minnesota, United States, 55905
Contact: Katrina Pierce, CCRP 507-266-1078 email@example.com
Principal Investigator: Megha M Tollefson, MD
Sub-Investigator: Lily C Wong-Kisiel, MD